Pediatric-type follicular lymphoma is a disease that affects the lymph nodes of the head and neck in the adult and pediatric patient groups. Ocular involvement is exceedingly rare, especially in the pediatrics age group; therefore, keeping a high clinical suspicion is warranted. Here, we report a rare conjunctival pediatric-type follicular lymphoma in a 15-year-old boy presenting with progressive swelling over the medial aspect of the left bulbar conjunctiva for two months. On examination, the mass was firm, mobile, well encapsulated, wide-based, and had a negative transillumination. An excisional biopsy was performed, and histopathological examination and immunohistochemistry studies revealed lymphoid tissue that was positive for CD20, CD79a, BCL6, and CD10; and negative for BCL2 and MUM1. The CD21 and CD23 positivity highlighted the presence of an expanded follicular dendritic cell meshwork. The patient was diagnosed with conjunctival pediatric-type follicular lymphoma and referred to an oncology center for further examination and treatment. This lymphoma is rare, requiring high clinical suspicion, and thus, reporting the case detail is important and valuable for ophthalmologists and general pediatrics practitioners alike.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919763PMC
http://dx.doi.org/10.7759/cureus.22023DOI Listing

Publication Analysis

Top Keywords

pediatric-type follicular
16
follicular lymphoma
16
conjunctival pediatric-type
12
high clinical
8
clinical suspicion
8
follicular
5
lymphoma
5
lymphoma young
4
young male
4
male case
4

Similar Publications

Pediatric lymphomas: overview and diagnostic challenges.

Virchows Arch

December 2024

Institute of Pathology and Neuropathology, Eberhard Karls University of Tuebingen and Comprehensive Cancer Center, University Hospital Tuebingen, Liebermeisterstr. 8, 72076, Tuebingen, Germany.

Only 10% of new lymphoma diagnoses in the USA occur in children < 15 years. Although the same diagnostic criteria apply to both adult and pediatric lymphomas, there are important differences in some lymphoma subtypes. These differences are recognized by the World Health Organization (WHO) with the recent 2022 classification of pediatric tumors including pediatric hematopoietic tumors.

View Article and Find Full Text PDF
Article Synopsis
  • Pediatric-type follicular lymphoma (PTFL) and pediatric nodal marginal zone lymphoma (PNMZL) are rare, slow-growing B-cell lymphomas with shared characteristics, prompting analysis of 59 patient cases for common features.
  • Most patients were young males (median age 17) with lymph node involvement, primarily in the head and neck region, and a significant majority opted for a watch-and-wait approach post-surgery.
  • Genetic analysis revealed shared mutations, suggesting that PTFL and PNMZL might actually be two manifestations of the same underlying disease rather than distinct conditions.
View Article and Find Full Text PDF

The authors present two cases of conjunctival pediatric-type follicular lymphoma. A 14-year-old Black boy and 14-year-old Black girl were each referred for evaluation of a painless salmon-colored conjunctival lesion. Both patients underwent excisional biopsy.

View Article and Find Full Text PDF

Indolent lymphomas are rare in children and mostly consist of pediatric type follicular (PTFL) and pediatric marginal zone lymphomas (PMZL) and extranodal marginal zone lymphoma (ENMZL). Twenty children with indolent lymphoma (10 PTFL, 6 PMZL, 3 ENMZL, 1 mixed type) among 307 Non-Hodgkin Lymphoma (NHL) were retrospectively evaluated. The mean age of the entire group was 10.

View Article and Find Full Text PDF

Pediatric-type follicular lymphoma in a Crohn's disease patient receiving anti-α4β7-integrin therapy: A case report.

World J Gastroenterol

November 2023

Pediatric Hematology/Oncology and Bone Marrow Transplantation, Cleveland Clinic Children's, Cleveland, OH 44106, United States.

Background: Patients with autoimmune conditions receiving immunosuppressants are at risk of non-Hodgkin lymphomas (NHL). Vedolizumab (anti-α4β7-integrin antibody), a treatment-of-choice for Crohn's disease (CD), reduces inflammatory lymphocyte trafficking into the intestinal mucosa. This effect is believed to be confined to the colon.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!